Inhibition of HSP90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cells

Multiple myeloma (MM) is the second most common hematologic malignancy. In spite of the development of new therapeutic agents, MM remains incurable due to multidrug resistance (MDR) and the 5-year survival rate is approximately 50%. Thus, further study is needed to investigate the mechanism of MDR a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical and experimental medicine 2020-02, Vol.20 (1), p.63-71
Hauptverfasser:	Tabata, Mitsuki, Tsubaki, Masanobu, Takeda, Tomoya, Tateishi, Keisuke, Maekawa, Saho, Tsurushima, Katsumasa, Imano, Motohiro, Satou, Takao, Ishizaka, Toshihiko, Nishida, Shozo
Format:	Artikel
Sprache:	eng
Schlagworte:	AKT protein Antineoplastic Agents - pharmacology Cell activation Cell Line, Tumor Cell Proliferation - drug effects Cell Survival - drug effects Down-Regulation Drug Resistance, Neoplasm - drug effects Drug Synergism Endoplasmic reticulum Endoplasmic Reticulum Stress - drug effects Gene Expression Regulation, Neoplastic - drug effects Heat shock proteins Hematology HSP90 Heat-Shock Proteins - antagonists & inhibitors HSP90 Heat-Shock Proteins - metabolism Hsp90 protein Humans Internal Medicine Isoxazoles - pharmacology Malignancy Medical prognosis Medicine Medicine & Public Health Melphalan Melphalan - pharmacology Morpholines - pharmacology Multidrug resistance Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - metabolism NF-κB protein Oncology Original Article Protein folding Resorcinols - pharmacology Signal Transduction - drug effects Src protein src-Family Kinases - metabolism Unfolded Protein Response - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!